Effect of apricoxib, a novel COX-2 inhibitor, on the efficacy of standard therapy in human pancreatic cancer cell lines in vitro and in vivo

被引：1
|
作者：
Kirane, A. R. [1 ]
机构：
[1] Univ Texas Southwestern, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
227
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo
    Liu, Jun-Feng
    Zhang, Shao-Wei
    Jamieson, Glyn G.
    Zhu, Gui-Jun
    Wu, Tie-Cheng
    Zhu, Tie-Nian
    Shan, Bao-En
    Drew, Paul A.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (07) : 1639 - 1644
  • [42] Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo
    Ogasawara, Sachiko
    Mihara, Yutaro
    Kondo, Reiichiro
    Kusano, Hironori
    Akiba, Jun
    Yano, Hirohisa
    [J]. ANTICANCER RESEARCH, 2019, 39 (11) : 5973 - 5982
  • [43] In vitro activity and in vivo efficacy of a benzazepinone ALK inhibitor on human neuroblastoma-derived cell lines
    Lu, Lihui
    Quail, Mattew
    Jones, Melissa
    Ghose, Monalisa
    DeVine, Ann
    Gregory, Gregory
    Jones-bolin, Susan
    Dorsey, Bruce
    Ruggeri, Bruce
    Cheng, Mangeng
    [J]. CANCER RESEARCH, 2009, 69
  • [44] Cyclooxygenase-2 (COX-2) independent tumor-killing effect of chemical COX-2 inhibitors compared to small interfering RNA of COX-2 in head and neck cancer cell lines
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (01): : 58 - 59
  • [45] Biomarker based phase I study of Apricoxib, a potent COX-2 inhibitor in combination with erlotinib in non-small cell lung cancer (NSCLC) patients
    Reckamp, Karen
    Patel, Ravi
    Gitlitz, Barbara
    Chen, Lin
    Jezior, Deborah
    Zaknoen, Sara
    [J]. CANCER RESEARCH, 2009, 69
  • [46] From COX-2 inhibitor nimesulide to potent anti-cancer agent: Synthesis, in vitro, in vivo and pharmacokinetic evaluation
    Zhong, Bo
    Cai, Xiaohan
    Chennamaneni, Snigdha
    Yi, Xin
    Liu, Lili
    Pink, John J.
    Dowlati, Afshin
    Xu, Yan
    Zhou, Aimin
    Su, Bin
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2012, 47 : 432 - 444
  • [47] In vitro metabolism of the Cox-2 inhibitor DFU, including a novel glutathione adduct rearomatization
    Yergey, JA
    Trimble, LA
    Silva, J
    Chauret, N
    Li, C
    Therien, M
    Grimm, E
    Nicoll-Griffith, DA
    [J]. DRUG METABOLISM AND DISPOSITION, 2001, 29 (05) : 638 - 644
  • [48] Synergistic effects of lovastatin and a COX-2 inhibitor on apoptosis, cell cycle arrest, prostaglandin synthesis and cell morphology in pancreatic cancer
    Vona-Davis, Linda
    Lopez, Lesly
    Olive, Mary
    Berrebi, Alexander
    McFadden, David
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [49] Characterization of Eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo
    Klein, Thomas
    Dullweber, Frank
    Brehm, Christoph
    Prinz, Walter
    Baudler, Monika
    Figala, Volker
    Hermann, Michael
    [J]. BIOCHEMICAL PHARMACOLOGY, 2008, 76 (06) : 717 - 725
  • [50] Anticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Lines
    Altun, Ahmet
    Turgut, Nergiz Hacer
    Kaya, Tijen Temiz
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (07) : 3113 - 3121
12345